

# Nanoco

Interim results

## Progressing sensing opportunity

During H121 Nanoco successfully delivered on the technical and commercial milestones for its programme with a major customer to develop new nanomaterials for sensing applications. Management implemented further restructuring actions, cutting cash-burn to £0.4m/month and extending the cash runway to calendar H222.

Year end	Revenue (£m)	EBITDA (£m)	PBT* (£m)	EPS* (p)	DPS (x)	P/E (x)
07/19	7.1	(3.8)	(5.0)	(1.34)	0.00	N/A
07/20	3.9	(2.9)	(4.9)	(1.38)	0.00	N/A
07/21e	1.4	(3.0)	(4.4)	(1.13)	0.00	N/A
07/22e	2.0	(2.2)	(3.6)	(0.97)	0.00	N/A

Note: \*PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

## Achieved milestones on sensing project

Nanoco's development activities have continued throughout the coronavirus-related restrictions. Revenues decreased by £1.9m year-on-year during H121 to £1.0m as revenues from the development work for the major customer, who we infer is ST Microelectronics (ST) based on previous announcements, were lower than those from the contract with the major US customer, which ended in December 2019. However, cost reductions meant that adjusted EBITDA losses only widened from £1.1m to £1.5m. Net cash (excluding the £0.5m convertible loan and £0.9m IFRS 16 lease liabilities) fell by £2.3m during the period to £2.9m at end-January 2021. We change our estimates to assume that Nanoco and ST move to commercial production in calendar H222, ie FY23 rather than calendar H122 (FY22), resulting in a £0.6m funding gap, which we model as satisfied through debt.

## Near-term opportunities in sensing

Nanoco's nanomaterials represent a cost-effective, proven way of improving the sensitivity of sensors used for facial recognition and augmented reality (AR) applications in mobile phones, automotive applications and IoT (internet of things) applications. Either of the two ongoing development programmes in sensing could potentially scale up to the £6m revenues required for break-even and lead to volume production of materials using the existing nanomaterials facility in Runcorn which has capacity to output materials worth £100m per year.

## Valuation: Resolution of patent infringement is key

The ongoing dialogue with ST confirms that there remains significant potential for generating revenues from the supply of quantum dots (QDs) for sensing applications. Ahead of development projects moving to commercial production we believe that at this point Nanoco's value lies in a satisfactory resolution of the patent infringement dispute with Samsung. Although the value of the potential payout has not been disclosed, we calculate that lost revenue in the US attributable to the patent infringement to date could be in the region of US\$200–250m or more. Any damages award could also make an additional allowance for future sales of Samsung TVs using QDs and sales in other territories.

## Tech hardware & equipment

30 March 2021

**Price** **23p**
**Market cap** **£69m**

Net cash (£m) at end January 2021 (excluding £0.5m convertible loan and £0.9m IFRS 16 lease liabilities) 2.9

Shares in issue 305.7m

Free float 70.0%

Code NANO

Primary exchange LSE

Secondary exchange N/A

## Share price performance



%	1m	3m	12m
Abs	49.0	116.4	138.1
Rel (local)	43.7	111.4	87.4
52-week high/low		23p	9p

## Business description

Nanoco is a global leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials. Its platform includes c 740 patents and specialist manufacturing lines. Focus applications are advanced electronics sensing, displays, and bio-imaging.

## Next event

FY21 results October 2021

## Analysts

Anne Margaret Crow +44 (0)20 3077 5700

Dan Ridsdale +44 (0)20 3077 5729

[tech@edisongroup.com](mailto:tech@edisongroup.com)
[Edison profile page](#)

**Nanoco is a research client of  
Edison Investment Research  
Limited**

## Financial performance

### H121 performance shaped by sensing activity

During H121 Nanoco successfully delivered all of the technical and commercial milestones for its major sensing project, which contributed £0.8m of the total £1.0m revenues for the period. This contrasted with H120 when Nanoco successfully delivered the final milestones on its contract with its former US customer which contributed £2.5m of the total £2.9m for the period. Adjusted EBITDA losses widened from £1.1m to £1.5m year-on-year. The relatively modest worsening of losses compared with the reduction in revenues demonstrates the benefit of the restructuring programmes that took place in H220 and H121. R&D costs fell by £0.4m or 26% year-on-year and administrative costs (after stripping out share-based payments and exceptional items), fell by £1.3m or 38%. The cost reduction programme has cut the average monthly cash burn from £0.7m in H120 to £0.4m.

Net cash (excluding the £0.5m convertible loan and £0.9m IFRS 16 lease liabilities) fell by £2.3m during the period to £2.9m at end January 2021. Investment in tangible assets was minimal. Intangibles expenditure of £0.2m related to patent costs. The prior year tax credit of £0.9m was received in January 2021.

### Outlook and estimates – cash runway extends to calendar H222

We leave our FY21 estimates broadly unchanged, adjusting indirect costs and share-based payments in line with H121 levels. We change our FY22 estimates to assume that Nanoco and ST move to commercial production in the calendar H222 ie FY23 rather than calendar H122 (FY22). This leaves a £0.6m financing gap, which we model as satisfied by debt, in line with our policy.

Exhibit 1: Changes to estimates							
Y/E August	FY20			FY21		FY22	
£'m	Actual	New	Old	% change	New	Old	% change
Revenues	3.9	1.4	1.4	0.0%	2.0	3.2	-37.5%
Gross profit	3.5	1.2	1.3	-6.9%	1.7	2.7	-35.6%
EBITDA	(2.9)	(3.0)	(2.9)	3.7%	(2.2)	(1.3)	68.1%
Normalised PBT	(4.9)	(4.4)	(4.4)	-0.8%	(3.6)	(2.6)	36.9%
Normalised net income	(4.0)	(3.5)	(3.5)	-0.9%	(3.0)	(2.0)	48.0%
Normalised diluted EPS	(1.4)	(1.1)	(1.1)	-0.9%	(1.0)	(0.7)	48.0%
Net debt/(cash)	(5.2)	(2.1)	(2.2)	-5.0%	0.6	(0.5)	-225.5%

Source: Edison Investment Research

Management's target is to progress nanomaterial development and scale-up programmes so the company reaches break-even, which management estimates is achievable on annual revenues of c £6m, within three years. Management estimates that Nanoco has sufficient cash to continue its existing business activities until partway through FY22, so it is aiming to either generate additional organic revenues to resolve the cash deficit or to undertake a major restructuring exercise, removing the group's R&D, production and scale-up capabilities to focus on pursuing the lawsuit against Samsung. The cash runway extends to the middle of calendar 2022 in this scenario. If one or more of the programmes does start to scale up, which would be likely in itself to extend the cash runway, we believe Nanoco would be well-placed to raise further finance at that point.

## Realising value through organic activities

### Near-term opportunities in sensing

Although the major US customer decided in June 2019 not to progress to volume production of nanomaterials for use in infra-red (IR) sensors, successful commissioning of the nanomaterials

production facility in Runcorn clearly demonstrates that Nanoco is able to deliver this material in commercial volumes. There is continued interest in using these nanomaterials to improve the sensitivity of silicon-based IR sensors. This is because nanomaterial-enhanced silicon sensors potentially provide a cost-effective route for improving the range and sensitivity of sensors currently used for facial recognition and AR applications in mobile phones and for IoT applications. Enhanced sensitivity results in lower power consumption, which for a mobile phone user means longer time between charges.

Nanoco and STMicroelectronics were part of a supply chain for the major US customer, with Nanoco manufacturing nanomaterials that ST used to improve the sensitivity of its silicon IR sensors. Now that the US customer has withdrawn from the scene, at least for the moment, and the exclusivity agreement with it has lapsed, we understand that ST is able to offer these enhanced, proven, near IR sensors across its extensive, global customer base. In May 2020, Nanoco signed a framework agreement with ST that covers both development work and the commercial supply of nanomaterials for use in multiple IR sensing applications over a five-year period. Subsequent purchase orders cover the supply of small-scale volumes of nanomaterials for the proven sensing application. The agreement also covered a project extending from April to December 2020 on a new generation of nanomaterials for potential use in other IR-sensing applications. Nanoco successfully delivered all the technical and commercial milestones on this project and is continuing to work with ST while the two parties negotiate the potential next phase of their work together. As the framework agreement commits ST to taking the majority of its nanomaterials from Nanoco if commercial volumes are required, the relationship gives a potential route for generating revenues from the existing nanomaterials facility in Runcorn, which has the capacity to manufacture c £100m of materials each year.

Nanoco has recently developed a new customer relationship for sensing applications with a significant participant in another major electronics supply chain. The relationship is generating modest R&D services. It involves different material sets from the ST programme and a range of functional wavelengths of material. The group continues to invest in R&D and can now offer materials that can absorb much longer wavelengths of IR light at specifically targeted bands such as 1,400nm, 1,550nm and 1,800nm. Longer wavelengths are eye-safe and so are preferable for applications such as world-facing cameras for AR functionality.

## **Display – small-scale activity at present**

Display remains an important market for Nanoco. While its activities in this area have reduced following the end of the long-term collaboration with Merck in June 2020, the group has formed relationships with new customers, a number of whom are evaluating existing materials for use in TV displays. This activity is modest at present. Samsung currently dominates the market for TV displays containing cadmium-free QDs with, according to management estimates, around a 90% market share. If competitors such as Hisense, Huawei, TCL or Vizio were to capture material market share, this could represent an opportunity for Nanoco to reactivate its mothballed production facility dedicated to display applications which has the capacity to manufacture c £30m of materials each year.

## **Grant underpins the future of Nanoco's life sciences activity**

In November 2020 Nanoco secured just under £1m in grant funding for a life sciences project to develop a heavy metal-free QD testing kit to detect COVID-19. The project will last 18 months and represents a potential third segment for generating future revenues.

## Patent infringement lawsuit against Samsung

---

Nanoco's other route for generating value for shareholders is the successful conclusion of its patent lawsuit against Samsung which it announced in February 2020. The lawsuit alleges that Samsung has wilfully infringed the patents relating to Nanoco's unique synthesis and resin capabilities for QDs. Nanoco is seeking a permanent injunction from further acts of infringement and unspecified but significant monetary damages. Nanoco and Samsung initially worked together to develop cadmium-free QDs based on Nanoco's IP. However, in 2015 Samsung ended the collaboration and launched its QD-based televisions without entering into a supply or licensing agreement with Nanoco.

Nanoco has engaged US-based international IP law firm Mintz, Levin, Cohn, Ferris, Glovsky and Popeo to represent it in patent enforcement and litigation and signed a litigation funding agreement with a very large, undisclosed US litigation finance specialist which means that Nanoco will be able to actively progress the lawsuit without adversely affecting its cash consumption. The jury trial is scheduled for October 2021. The claim construction (Markman) hearing preparatory to the trial was held on 26 March 2021. This hearing established the court's interpretation of certain words or phrases pertinent to the patents and the case which may be important to either side's arguments. Management expects to receive the judge's final written report on the Markman hearing before the end of May 2021.

In a parallel process to the litigation, Samsung has requested that the Patent Trial and Appeal Board (PTAB) institute a formal validity review of each patent asserted in the lawsuit via inter parties reviews (IPRs). Management expects that the PTAB will decide whether or not to institute IPRs in May 2021, a process which can then take up to 12 months. We note that it could take two or more years for any successful verdict or damages award to be enforced because of the appeals process applicable to both the judicial trial and PTAB processes.

Nanoco has not revealed its estimates of the potential payout if the litigation is successful but has stated that since April 2015 Samsung had sold 14 million TVs deploying QDs based on Nanoco IP in the US. These TVs had an average sales price of US\$2,200–2,500 compared with the average price of a top of the range TV without QDs of c US\$1,000. The value of the lost revenue to Nanoco this represents has not been disclosed. Had the alleged patent infringement not taken place, we believe Nanoco would have collected royalties from its partners, primarily Dow Chemical, which would potentially be supplying QDs to Samsung in volumes higher than Nanoco could produce itself in Runcorn. If we assume that the cost of the QDs in each TV is equivalent to 10% of the uplift in price between QD and non-QD TV displays, and that Nanoco would have received a 12% royalty (as per our May 2017 [initiation note](#)) on these QDs, this represents US\$14.4–18.0 in lost revenue per TV display or US\$200–250m between April 2015 and the present. This value excludes QDs in any future TV displays Samsung makes or TVs sold in other territories. We note that around one-third of Samsung's TV sales are attributable to the US market.

**Exhibit 2: Financial summary**

	£m	2019	2020	2021e	2022e
31-July		IFRS	IFRS	IFRS	IFRS
<b>INCOME STATEMENT</b>					
Revenue		7.1	3.9	1.4	2.0
Cost of Sales		(0.7)	(0.3)	(0.2)	(0.3)
Gross Profit		6.5	3.5	1.2	1.7
EBITDA		(3.8)	(2.9)	(3.0)	(2.2)
Operating profit (before amort. and except).		(5.0)	(4.8)	(4.3)	(3.5)
Amortisation of acquired intangibles		0.0	0.0	0.0	0.0
Exceptionals		(0.3)	(0.7)	0.0	0.0
Share-based payments		(0.2)	(0.4)	(0.6)	(0.6)
Reported operating profit		(5.5)	(5.9)	(4.9)	(4.1)
Net Interest		(0.0)	(0.1)	(0.1)	(0.1)
Joint ventures & associates (post tax)		0.0	0.0	0.0	0.0
Exceptionals		0.0	0.0	0.0	0.0
Profit Before Tax (norm)		(5.0)	(4.9)	(4.4)	(3.6)
Profit Before Tax (reported)		(5.5)	(6.0)	(4.9)	(4.1)
Reported tax		1.2	0.9	0.9	0.6
Profit After Tax (norm)		(3.9)	(4.0)	(3.5)	(3.0)
Profit After Tax (reported)		(4.4)	(5.1)	(4.0)	(3.5)
Minority interests		0.0	0.0	0.0	0.0
Net income (normalised)		(3.9)	(4.0)	(3.5)	(3.0)
Net income (reported)		(4.4)	(5.1)	(4.0)	(3.5)
Average Number of Shares Outstanding (m)		286	287	306	306
EPS - normalised (p)		(1.34)	(1.38)	(1.13)	(0.97)
EPS - diluted normalised (p)		(1.34)	(1.38)	(1.13)	(0.97)
EPS - basic reported (p)		(1.52)	(1.76)	(1.32)	(1.16)
Dividend per share (p)		0.00	0.00	0.00	0.00
<b>BALANCE SHEET</b>					
Fixed Assets		4.6	4.6	4.1	3.6
Intangible Assets		3.9	3.7	3.5	3.3
Tangible Assets		0.7	0.9	0.5	0.3
Investments & other		0.0	0.0	0.0	0.0
Current Assets		9.5	7.2	4.1	2.2
Stocks		0.2	0.1	0.1	0.2
Debtors		1.1	1.0	1.0	1.1
Cash & cash equivalents		7.0	5.2	2.1	(0.0)
Other		1.1	0.9	0.9	0.9
Current Liabilities		(4.8)	(3.4)	(3.4)	(4.0)
Creditors		(2.6)	(2.1)	(2.1)	(2.2)
Tax and social security		0.0	0.0	0.0	0.0
Short term financial leases		0.0	(0.6)	(0.6)	(0.6)
Short term bank debt		0.0	0.0	0.0	(0.6)
Other		(2.3)	(0.6)	(0.6)	(0.6)
Long Term Liabilities		(0.8)	(1.3)	(1.1)	(1.0)
Long term financial leases		0.0	(0.5)	(0.3)	(0.2)
Long term bank debt		0.0	0.0	0.0	0.0
Other long term liabilities		(0.8)	(0.7)	(0.7)	(0.7)
Net Assets		8.5	7.2	3.8	0.8
Minority interests		0.0	0.0	0.0	0.0
Shareholders' equity		8.5	7.2	3.8	0.8
<b>CASH FLOW</b>					
Op Cash Flow before WC and tax		(3.8)	(2.9)	(3.0)	(2.2)
Working capital		1.8	(1.5)	0.0	(0.1)
Exceptional & other		0.0	(0.2)	0.0	0.0
Tax		1.4	1.1	0.9	0.6
Net operating cash flow		(0.6)	(3.5)	(2.1)	(1.7)
Capex		(3.1)	(0.7)	(0.7)	(0.8)
Acquisitions/disposals		0.0	0.0	0.0	0.0
Net interest		(0.0)	(0.1)	(0.1)	(0.1)
Equity financing		0.0	3.2	0.0	0.0
Dividends		0.0	0.0	0.0	0.0
Other		0.0	0.0	(0.2)	(0.1)
Net Cash Flow		(3.7)	(1.1)	(3.1)	(2.7)
Opening net debt/(cash) (excluding finance leases)		(10.7)	(7.0)	(5.2)	(2.1)
FX		0.0	0.0	0.0	0.0
Other non-cash movements		0.0	(0.8)	0.0	0.0
Closing net debt/(cash) (excluding finance leases)		(7.0)	(5.2)	(2.1)	0.6

Source: Company data, Edison Investment Research

---

## General disclaimer and copyright

This report has been commissioned by Nanoco and prepared and issued by Edison, in consideration of a fee payable by Nanoco. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

**Accuracy of content:** All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

**Exclusion of Liability:** To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

**No personalised advice:** The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

**Investment in securities mentioned:** Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2021 Edison Investment Research Limited (Edison).

---

## Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

---

## New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

---

## United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

---

## United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960  
Schumannstrasse 34b  
60325 Frankfurt  
Germany

London +44 (0)20 3077 5700  
280 High Holborn  
London, WC1V 7EE  
United Kingdom

New York +1 646 653 7026  
1185 Avenue of the Americas  
3rd Floor, New York, NY 10036  
United States of America

Sydney +61 (0)2 8249 8342  
Level 4, Office 1205  
95 Pitt Street, Sydney  
NSW 2000, Australia